Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Age Ageing ; 53(5)2024 05 01.
Article in English | MEDLINE | ID: mdl-38706390

ABSTRACT

BACKGROUND: Acute gastrointestinal bleeding (AGIB) is common in older patients but the use of iron in this context remains understudied. AIMS: This study aimed to evaluate prospectively the efficacy of ferric carboxymaltose to treat anaemia in older patients after AGIB. METHODS: This randomised double-blinded placebo-controlled clinical trial was conducted in 10 French centres. Eligible patients were 65 years or more, had controlled upper or lower gastrointestinal bleeding and a haemoglobin level of 9-11 g/dl. Patients were randomly assigned, in a 1:1 ratio, to receive either one intravenous iron injection of ferric carboxymaltose or one injection of saline solution. The primary endpoint was the difference in haemoglobin level between day 0 and day 42. Secondary endpoints were treatment-emergent adverse events, serious adverse events, rehospitalisation and improvement of quality of life (QOL) at day 180. RESULTS: From January 2013 to January 2017, 59 patients were included. The median age of patients was 81.9 [75.8, 87.3] years. At day 42, a significant difference in haemoglobin level increase was observed (2.49 g/dl in the ferric carboxymaltose group vs. 1.56 g/dl in the placebo group, P = 0.02). At day 180, QOL, measured on European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, improved by 10.5 points in the ferric carboxymaltose group and by 8.2 points in the placebo group (P = 0.56). Rates of adverse events and rehospitalisation were similar in the two groups. CONCLUSIONS: Intravenous iron seems safe and effective to treat anaemia in older patients after AGIB and should be considered as a standard-of-care treatment. ClinicalTrials.gov (NCT01690585).


Subject(s)
Ferric Compounds , Gastrointestinal Hemorrhage , Hemoglobins , Maltose , Maltose/analogs & derivatives , Quality of Life , Humans , Ferric Compounds/adverse effects , Ferric Compounds/administration & dosage , Ferric Compounds/therapeutic use , Male , Maltose/administration & dosage , Maltose/adverse effects , Maltose/therapeutic use , Female , Aged , Hemoglobins/metabolism , Hemoglobins/analysis , Gastrointestinal Hemorrhage/drug therapy , Aged, 80 and over , Double-Blind Method , Treatment Outcome , Prospective Studies , Hematinics/adverse effects , Hematinics/administration & dosage , Hematinics/therapeutic use , France , Injections, Intravenous , Age Factors
2.
J Clin Med ; 9(1)2019 Dec 24.
Article in English | MEDLINE | ID: mdl-31878146

ABSTRACT

Despite the development of novel therapies, inflammatory bowel diseases remain an innovative treatment challenge. Helminth therapy is a new promising approach, and a key issue is the identification of helminth-derived anti-inflammatory mediators. P28 glutathione-S-transferase (P28GST), a protein derived from schistosomes, a trematode parasitic helminth, was shown to reduce intestinal inflammation in experimental colitis by down-regulating the Th1/Th17 response. In this multicenter, open-label, pilot Phase 2a study, we evaluated the safety of P28GST administered to patients with mild Crohn's disease (CD). We enrolled 10 patients with a baseline Crohn's disease activity index (CDAI) value <220. Eight patients received two to three subcutaneous injections of recombinant P28GST with adjuvant. This three-month treatment was followed by a nine-month monitoring period. The primary endpoints were the monthly rate and seriousness of adverse events (AEs). Secondary endpoints were clinical recurrence, assessed with the CDAI as well as the levels of immunologic and inflammatory blood and tissue markers. The most common AEs were local or regional events at the injection site and gastrointestinal disorders. At three months after the first injection, CDAI scores and blood calprotectin levels decreased in parallel. These results indicate that P28GST showed promise as a safe and new therapeutic option for treating CD.

3.
Clin Res Hepatol Gastroenterol ; 43(3): 338-345, 2019 06.
Article in English | MEDLINE | ID: mdl-30528512

ABSTRACT

INTRODUCTION: In Europe, the number of cases of Campylobacter enteritis and their quinolone resistance is increasing. The aims of this work were to evaluate: (1) the hospital epidemiology of bacterial enteritis between 2010 and 2015. (2) The proportion of Campylobacter and Salmonella enteritis. (3) Resistance to quinolones in adult and paediatric populations. (4) To investigate possible regional epidemiological and bacteriological disparities. PATIENTS AND METHODS: This is a multicentric study carried out in 21 general hospitals (CHG) representing 14 French regions with a prospective collection of the results of coprocultures from 2010 to 2015 in adult and paediatric populations (children < 15 years old not exposed to quinolones). The epidemiological and bacteriological data were collected from software laboratory for positive stool cultures for Campylobacter and Salmonella. The results were compared year by year and by a period of 2 years. RESULTS: In adults, Campylobacter enteritis was each year significantly more frequent than Salmonella (P < 0.001), with a significant increase from 2010 to 2015 (P < 0.05). In children, there was also a significant and stable predominance of Campylobacter enteritis over the study period (P = 0.002). The quinolone resistance of Campylobacter was greater than 50% on the whole territory, with no North-South difference over the three periods studied. It increased significantly from 2012 to 2015 in adults (48% to 55%, P < 0.05) and in children (54% to 61%, P = 0.04). CONCLUSION: Our results confirm the increase in the prevalence of Campylobacter enteritis compared to Salmonella between 2010 and 2015. The quinolone resistance of Campylobacter is greater than 50% on the whole territory, stable between 2010 and 2015 in adults and significantly increased in children.


Subject(s)
Campylobacter Infections/epidemiology , Enteritis/epidemiology , Enteritis/microbiology , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , Drug Resistance, Bacterial , France/epidemiology , Hospitals, General , Humans , Incidence , Middle Aged , Retrospective Studies , Salmonella Infections/epidemiology , Seasons , Young Adult
5.
Pancreatology ; 13(1): 90-4, 2013.
Article in English | MEDLINE | ID: mdl-23395576

ABSTRACT

INTRODUCTION: Autoimmune pancreatitis is an idiopathic inflammatory disease that produces pancreatic masses and ductal strictures. This benign disease can be associated with extrapancreatic manifestations including cholangitis, sialadenitis, inflammatory bowel disease or retroperitoneal fibrosis, mediastinal adenopathy, interstitial nephritis mainly due to immunoglobulin G4 (Ig G4), and occasional association with other auto-immune diseases. OBSERVATION: We report a 57-year-old woman who developed thrombotic thrombocytopenic purpura (TTP) and pseudo-tumour's seronegative autoimmune pancreatitis (AIP) type 1. The patient was initially treated with pulse corticosteroids and plasmapheresis; afterwards two cures of i.v. Vincristin with inadequate response and subsequently with four weekly pulses dose of i.v. Rituximab, leading to full remission. CONCLUSION: This case represents the first report of TTP associated to pseudo-tumour's seronegative AIP type 1 successfully treat by Rituximab.


Subject(s)
Autoimmune Diseases/etiology , Pancreatitis/etiology , Purpura, Thrombotic Thrombocytopenic/complications , Anti-Inflammatory Agents/therapeutic use , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Autoimmune Diseases/drug therapy , Female , Humans , Middle Aged , Pancreatitis/drug therapy , Rituximab
7.
Gastroenterol Clin Biol ; 31(6-7): 624-6, 2007.
Article in French | MEDLINE | ID: mdl-17646794

ABSTRACT

We report the case of a 77 year old man treated with a distal pancreatectomy for rectal metastatic cancer. Diagnosis was made based on increased CEA levels following excision of the rectal tumor discovered during treatment follow up of liver and pulmonary metastases. Eight months after pancreatectomy the patient was asymptomatic and CEA levels were normal. Pancreatic resection for metastatic colonic adenocarcinoma of the pancreas may be considered in selected patients without extrapancreatic disease. Long-term survival or good palliation may be achieved after surgery.


Subject(s)
Adenocarcinoma/secondary , Adenocarcinoma/surgery , Neoplasms, Second Primary/surgery , Pancreatectomy/methods , Pancreatic Neoplasms/secondary , Pancreatic Neoplasms/surgery , Rectal Neoplasms/pathology , Rectal Neoplasms/surgery , Aged , Digestive System Surgical Procedures , Humans , Male , Time Factors
11.
Pancreatology ; 5(4-5): 450-6, 2005.
Article in English | MEDLINE | ID: mdl-15985771

ABSTRACT

BACKGROUND: No study on bioclinical criteria predicting a biliary origin for acute pancreatitis has included endosonography as a reference examination. Re-examination of bioclinical parameters deserves consideration in the era where other causes are known (e.g. hereditary, autoimmune). AIM AND METHODS: To determine the performance of bioclinical markers in predicting a biliary origin of acute pancreatitis where the diagnosis of biliary lithiasis was established or ruled out using endosonography. Only patients with a first acute episode of pancreatitis were included. RESULTS: 213 patients (male: 55%; median age: 56 years) were prospectively included in 14 centres. Causes of acute pancreatitis were: biliary (62%), alcoholic (25%), other (13%). Delay between symptom-onset and admission was <48 h in 80%. Endosonography was the sole method establishing the diagnosis of biliary pancreatitis in 15% of patients. At univariate analysis, age, female sex, declared alcohol consumption, elevated aspartate and alanine transaminases on admission, gammaglutamyl transferase, alkaline phosphatase, total bilirubin, lipase, mean corpuscular volume were predictive of a biliary origin. Only age (p < 0.0001), sex (p < 0.0008) and alanine transaminase (p < 0.0004) remained significant at multivariate analysis. At age 50, the respective sensitivity and specificity were 73 and 65%. With an elevated alanine transaminase at 2 times the upper limit of normal range, the respective sensitivity and specificity were 74 and 84%. The probability of a biliary origin of acute pancreatitis could be estimated by the following formula: = 1/1 + exp(4.6967 - 0.0656 x age + 1.1208 x sex - 0.6909 x alanine transaminase). CONCLUSION: When endosonography is performed to confirm or exclude a biliary origin of acute pancreatitis, age, sex and alanine transaminase at admission are the only factors predictive of a biliary cause.


Subject(s)
Cholelithiasis/diagnosis , Endosonography/methods , Pancreatitis/diagnosis , Acute Disease , Adolescent , Adult , Aged , Aged, 80 and over , Alanine Transaminase/blood , Biomarkers/blood , Cholelithiasis/complications , Cholelithiasis/diagnostic imaging , Diagnosis, Differential , Female , Humans , Male , Middle Aged , Pancreatitis/diagnostic imaging , Pancreatitis/etiology , Pancreatitis, Alcoholic/complications , Pancreatitis, Alcoholic/diagnosis , Pancreatitis, Alcoholic/diagnostic imaging , Predictive Value of Tests , Risk Factors , Sensitivity and Specificity , Sex Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...